AbbVie Inc. reported Q2 2026 adjusted EPS of $3.65, beating estimates by $0.06, with strong growth in Rinvoq and neuroscience sales driving nearly $17 billion in revenue.
AbbVie Inc. reported Q2 2026 adjusted earnings per share (EPS) of $3.65, surpassing the consensus estimate of $3.59 by $0.06. This performance was driven largely by strong sales growth across its immunology and neuroscience segments, despite facing a decline in Humira sales due to biosimilar competition.
Key Takeaways
- Total revenue reached nearly $17 billion, up 10.2% year-over-year, reflecting robust growth in key therapeutic areas.
- Immunology sales were particularly strong, with Rinvoq global sales exceeding $2.5 billion, up 23.7% operationally.
- Neuroscience revenues surpassed $3.2 billion, up approximately 20%, bolstered by strong sales of Valar and Botox Therapeutic.
- Humira sales fell to $756 million, a decline of 36.1% operationally, consistent with expectations amid increasing biosimilar competition.
- Updated guidance raised full-year adjusted EPS to a range of $13.87 to $14.07, reflecting continued momentum and strategic growth initiatives.
Strong Growth in Immunology Drives Revenue
Total revenue for AbbVie grew to nearly $17 billion, marking a 10.2% increase year-over-year. This growth can largely be attributed to the continuing success of its immunology products. Rinvoq, which achieved global sales of more than $2.5 billion, reported a remarkable 23.7% operational increase, driven by its expanding label and aggressive market penetration in indications such as ulcerative colitis and Crohn's disease.
| Metric | Q2 2026 | YoY | QoQ |
|---|---|---|---|
| Revenue | $17B | +10.2% | +2.5% |
| Adjusted EPS | $3.65 | +8.1% | +3.5% |
| Rinvoq Sales | $2.5B | +23.7% | +5.0% |
| Humira Sales | $756M | -36.1% | -7.5% |
AbbVie continues to capture a significant share of new patient starts in the U.S. for Rinvoq, showcasing its physician preference in the competitive landscape of immunology. Management noted strong endoscopic response data supporting the upcoming subcutaneous induction dosing for Skyrizi in Crohn's disease, expected to drive further growth in the second half of 2026.
Neuroscience Portfolio Shows Robust Growth
Neuroscience revenues exceeded $3.2 billion, reflecting a 20% operational growth. Key contributors included Valar, which reported nearly $1.1 billion in sales, up approximately 19%, alongside Botox Therapeutic, which approached $4.2 billion. AbbVie’s ambitious pipeline in neuroscience, particularly with the anticipated launch of Tavapadon, is expected to further bolster this segment. Management expressed confidence in Tavapadone’s efficacy and its potential to achieve blockbuster sales, projecting over $5 billion in peak sales across their Parkinson's portfolio.
Updated Guidance Signals Continued Confidence
AbbVie provided an optimistic update to its full-year financial guidance, now projecting adjusted EPS between $13.87 and $14.07, an increase from prior estimates. This update reflects a $0.10 improvement based on second-quarter results and strong momentum in its existing business. Additionally, the company anticipates total net revenues of approximately $67.6 billion, marking an increase of $300 million from previous expectations. This outlook is buoyed by anticipated growth across multiple segments, particularly in immunology and neuroscience.
Analyst Q&A Highlights Competitive Dynamics
During the Q&A session, analysts queried management about competitive dynamics in the immunology space, particularly regarding Skyrizi and Rinvoq. Executives emphasized that while competition is intensifying, they have not observed any degradation in market share trends since the launch of competitive products. Instead, they noted that Skyrizi continues to experience growth in new starts, suggesting a market-expanding effect rather than direct competition.
Frequently Asked Questions
Did AbbVie Inc. beat earnings estimates in Q2 2026?
Yes, AbbVie reported adjusted EPS of $3.65, beating the consensus estimate of $3.59 by $0.06.
What were AbbVie’s total revenues for Q2 2026?
Total revenues for Q2 2026 reached nearly $17 billion, representing a 10.2% increase year-over-year.
How did Rinvoq perform in Q2 2026?
Rinvoq achieved global sales of over $2.5 billion in Q2 2026, reflecting a 23.7% operational increase compared to the prior year.
What is AbbVie’s updated guidance for the full year 2026?
AbbVie updated its full-year adjusted EPS guidance to a range of $13.87 to $14.07, reflecting continued growth momentum and strategic initiatives.
AbbVie’s strong performance in Q2 2026 underscores its leadership position in immunology and neuroscience, but ongoing competition and market dynamics will be critical to monitor as the company progresses into the second half of the year.
This analysis is based on public earnings call materials and is not investment advice.
